These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18829459)

  • 21. Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based peptide mimetic.
    Avdic V; Zhang P; Lanouette S; Voronova A; Skerjanc I; Couture JF
    FASEB J; 2011 Mar; 25(3):960-7. PubMed ID: 21135039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hierarchical assembly of the MLL1 core complex regulates H3K4 methylation and is dependent on temperature and component concentration.
    Namitz KEW; Tan S; Cosgrove MS
    J Biol Chem; 2023 Feb; 299(2):102874. PubMed ID: 36623730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of MLL1 H3K4 methyltransferase activity by its core components.
    Dou Y; Milne TA; Ruthenburg AJ; Lee S; Lee JW; Verdine GL; Allis CD; Roeder RG
    Nat Struct Mol Biol; 2006 Aug; 13(8):713-9. PubMed ID: 16878130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain.
    Cao F; Chen Y; Cierpicki T; Liu Y; Basrur V; Lei M; Dou Y
    PLoS One; 2010 Nov; 5(11):e14102. PubMed ID: 21124902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
    Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks.
    Southall SM; Wong PS; Odho Z; Roe SM; Wilson JR
    Mol Cell; 2009 Jan; 33(2):181-91. PubMed ID: 19187761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
    Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
    J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The MLL1 trimeric catalytic complex is a dynamic conformational ensemble stabilized by multiple weak interactions.
    Kaustov L; Lemak A; Wu H; Faini M; Fan L; Fang X; Zeng H; Duan S; Allali-Hassani A; Li F; Wei Y; Vedadi M; Aebersold R; Wang Y; Houliston S; Arrowsmith CH
    Nucleic Acids Res; 2019 Sep; 47(17):9433-9447. PubMed ID: 31400120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
    Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
    Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
    Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
    Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multistate structures of the MLL1-WRAD complex bound to H2B-ubiquitinated nucleosome.
    Rahman S; Hoffmann NA; Worden EJ; Smith ML; Namitz KEW; Knutson BA; Cosgrove MS; Wolberger C
    Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2205691119. PubMed ID: 36095189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
    Weirich S; Kudithipudi S; Jeltsch A
    Mol Oncol; 2017 Apr; 11(4):373-387. PubMed ID: 28182322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting MLL1-WDR5 interaction ameliorates neuropathic allodynia by attenuating histone H3 lysine 4 trimethylation-dependent spinal mGluR5 transcription.
    Lin TB; Lai CY; Hsieh MC; Ho YC; Wang HH; Yang PS; Cheng JK; Chen GD; Ng SC; Peng HY
    Pain; 2020 Sep; 161(9):1995-2009. PubMed ID: 32345914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
    Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
    Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
    Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
    J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein.
    Cosgrove MS; Patel A
    FEBS J; 2010 Apr; 277(8):1832-42. PubMed ID: 20236310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
    Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
    Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes.
    Wang Q; Yu M; Ma Y; Zhang X; Zhang H; Li S; Lan R; Lu F
    Lab Invest; 2018 Dec; 98(12):1627-1641. PubMed ID: 30089852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
    Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
    Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.